Bristol Myers Squibb highlights 3.5 years of sustained efficacy for Camzyos (mavacamten) in obstructive hypertrophic cardiomyopathy (#oHCM). New data from the MAVA-LTE study show lasting improvements in heart metrics, symptoms, and biomarkers. #Cardiology #Camzyos #BMS Follow Mellalta Meets

❤️ Matthew W. Martinez, MD, talks about new guidelines which recommend #CAMZYOS for the treatment of obstructive hypertrophic cardiomyopathy. #HCM #cardiology #cardiotwitter #cardioX American Heart Association American College of Cardiology 📺 Watch Now: buff.ly/3WYmJ3n

Congratulations to all participants in this year’s #PrixGalien / #Galenusprijs and especially to the 3 nominees: GSK for #Arexvy , Servier for #Tibsovo and to the winner Bristol Myers Squibb for #Camzyos ! Roularta Media Group #onderzoek #recherche Sally Ann McNab Gilles Poncé bartcroes

🧵 Cytokinetics Unveils Aficamten Data, Gears Up for Market Competition Against Camzyos #Cytokinetics #Aficamten #Camzyos #ClinicalData #CardiovascularDisease #MyotonicDystrophy #HeartFailure #CommercialStrategy #MarketCompetition

The #Federal #Government has #announced the #PBS #listing of #CAMZYOS for the #treatment of #adults with #obstructive #Hypertrophic Cardiomyopathy (HCM). 🫀 For more, head to: livhealth.com.au/australias-fir… Heart Support Australia @cmaa_aust

Stanowisko Rady Przejrzystości dla #lek #Camzyos (#mavacamtenum) we wskazaniu: Leczenie pacjentów z przerostową kardiomiopatią zawężającą (ICD-10 I42.1) Szczegóły 👉 bipold.aotm.gov.pl/assets/files/z… #leki #refundacja #przejrzystość Ministerstwo Zdrowia Maciej Miłkowski Narodowy Fundusz Zdrowia

@idaiced Bristol Myers Squibb Bristol Myers Squibb has announced that it will present data on #CAMZYOS (#mavacamten) for NYHA class II-III obstructive #hypertrophic_cardiomyopathy at #ACC24 dicardiology.com/content/bristo…

📣 New Podcast! "Dr. Williams Crowder and Stephanie discuss #HCM ~ #HeartHealthMonth #HypertrophicCardiomyopathy Hypertrophic Cardiomyopathy Medical Society #camzyos" on @Spreaker spreaker.com/episode/dr-wil…

$CYTK Bristol 1st-in-class HCM drug #Camzyos growing nicely. $88M this quarter. Bristol will be helpful in raising awareness.

#Camzyos, which works similarly to #aficamten, has a black box warning of a #heartfailure risk. FDA's 2022 approval of the $BMY drug required a REMS, an oversight program for drugs with serious safety risks. medcitynews.com/2022/04/potent…

.Cytokinetics cardio drug #aficamten met its Phase 3 goal in obstructive hypertrophic #cardiomyopathy, which can lead to #heartfailure. If approved, the small molecule would compete with Bristol Myers Squibb’s #Camzyos. $CYTK shares soared 82%+. medcitynews.com/2023/12/cytoki…

Learned about #Camzyos aka. #Mavacamten for #HOCM. Very interesting, novel mech. ⬇️ Myosin-actin cross bridging ♥️ NYHA II-III, LVEF >= 55% ⬆️ KCCQ & NYHA 👀 many drug interactions 🤰Contraindicated Holds promise, but more extensive studies would be nice! #CardioTwitter

Recommandations FLASH du Réseau Francophone de Pharmacogénétique #RNPGx pour l'analyse pharmacogénétique du #Mavacamten #Camzyos en #Cardiologie drive.google.com/file/d/1mFqZhT… Pour consulter la liste des laboratoires de recours pour l'analyse : google.com/maps/d/viewer?…

I need to call my mom. Our paper is featured on the cover of the current issue of the The FEBS Journal! Read more about this exciting work below.🫀🔬 #Mechanobiology #Biophysics #HCM #Mavacamten #Camzyos #OmecamtivMecarbil UIC Physiology UIC Research UICscience febs.onlinelibrary.wiley.com/doi/10.1111/fe…